Global Prostate Cancer Testing 麻豆原创 Research Report 2023

Publication ID:

PB502234169

Publication Date:

February 7, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Prostate cancer testing refers to the tests conducted for the detection, localization, grading, and staging of prostate carcinoma. The currently established methods of prostate cancer detection include digital rectal examination (DRE), serum prostate-specific antigen (PSA) tests, and transrectal ultrasound (TRUS)-guided prostate biopsy using a systematic 12-core method.
Highlights
The global Prostate Cancer Testing market was valued at US$ 14570 million in 2022 and is anticipated to reach US$ 22660 million by 2029, witnessing a CAGR of 7.6% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The high prevalence rate of prostate cancer is a key factor, which is driving the global market for the prostate cancer. Prostate cancer is the second-leading cause of death in the United States. According to National Cancer Institute, it is estimated that there were around 161,360 new cases of prostate cancer and an estimated 26,730 people will die due to it. Based on these statistics, we can see that the prevalence rate of prostate cancer is increasing across the world and hence, it is driving the market.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Prostate Cancer Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Prostate Cancer Testing.
The Prostate Cancer Testing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Prostate Cancer Testing market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Prostate Cancer Testing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Genomic Health
OPKO
Siemens Healthcare
DiaSorin
bioMeriux
Roche
MDx Health
Beckman Coulter
Myriad Genetics
Ambry Genetics
Segment by Type
PSA Tests
CTC Tests
Immunohistochemistry
PCA3 Tests
Others
Segment by Application
Hospital Associated Labs
Independent Diagnostic Laboratories
Cancer Research Institutes
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Prostate Cancer Testing companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Prostate Cancer Testing 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 PSA Tests
1.2.3 CTC Tests
1.2.4 Immunohistochemistry
1.2.5 PCA3 Tests
1.2.6 Others
1.3 麻豆原创 by Application
1.3.1 Global Prostate Cancer Testing 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Associated Labs
1.3.3 Independent Diagnostic Laboratories
1.3.4 Cancer Research Institutes
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Prostate Cancer Testing 麻豆原创 Perspective (2018-2029)
2.2 Prostate Cancer Testing Growth Trends by Region
2.2.1 Global Prostate Cancer Testing 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Prostate Cancer Testing Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Prostate Cancer Testing Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Prostate Cancer Testing 麻豆原创 Dynamics
2.3.1 Prostate Cancer Testing Industry Trends
2.3.2 Prostate Cancer Testing 麻豆原创 Drivers
2.3.3 Prostate Cancer Testing 麻豆原创 Challenges
2.3.4 Prostate Cancer Testing 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Prostate Cancer Testing Players by Revenue
3.1.1 Global Top Prostate Cancer Testing Players by Revenue (2018-2023)
3.1.2 Global Prostate Cancer Testing Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Prostate Cancer Testing 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Prostate Cancer Testing Revenue
3.4 Global Prostate Cancer Testing 麻豆原创 Concentration Ratio
3.4.1 Global Prostate Cancer Testing 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Prostate Cancer Testing Revenue in 2022
3.5 Prostate Cancer Testing Key Players Head office and Area Served
3.6 Key Players Prostate Cancer Testing Product Solution and Service
3.7 Date of Enter into Prostate Cancer Testing 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Prostate Cancer Testing Breakdown Data by Type
4.1 Global Prostate Cancer Testing Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Prostate Cancer Testing Forecasted 麻豆原创 Size by Type (2024-2029)
5 Prostate Cancer Testing Breakdown Data by Application
5.1 Global Prostate Cancer Testing Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Prostate Cancer Testing Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Prostate Cancer Testing 麻豆原创 Size (2018-2029)
6.2 North America Prostate Cancer Testing 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Prostate Cancer Testing 麻豆原创 Size by Country (2018-2023)
6.4 North America Prostate Cancer Testing 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Prostate Cancer Testing 麻豆原创 Size (2018-2029)
7.2 Europe Prostate Cancer Testing 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Prostate Cancer Testing 麻豆原创 Size by Country (2018-2023)
7.4 Europe Prostate Cancer Testing 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Prostate Cancer Testing 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Prostate Cancer Testing 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Prostate Cancer Testing 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Prostate Cancer Testing 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Prostate Cancer Testing 麻豆原创 Size (2018-2029)
9.2 Latin America Prostate Cancer Testing 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Prostate Cancer Testing 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Prostate Cancer Testing 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Prostate Cancer Testing 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Prostate Cancer Testing 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Prostate Cancer Testing 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Prostate Cancer Testing 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Genomic Health
11.1.1 Genomic Health Company Detail
11.1.2 Genomic Health Business Overview
11.1.3 Genomic Health Prostate Cancer Testing Introduction
11.1.4 Genomic Health Revenue in Prostate Cancer Testing Business (2018-2023)
11.1.5 Genomic Health Recent Development
11.2 OPKO
11.2.1 OPKO Company Detail
11.2.2 OPKO Business Overview
11.2.3 OPKO Prostate Cancer Testing Introduction
11.2.4 OPKO Revenue in Prostate Cancer Testing Business (2018-2023)
11.2.5 OPKO Recent Development
11.3 Siemens Healthcare
11.3.1 Siemens Healthcare Company Detail
11.3.2 Siemens Healthcare Business Overview
11.3.3 Siemens Healthcare Prostate Cancer Testing Introduction
11.3.4 Siemens Healthcare Revenue in Prostate Cancer Testing Business (2018-2023)
11.3.5 Siemens Healthcare Recent Development
11.4 DiaSorin
11.4.1 DiaSorin Company Detail
11.4.2 DiaSorin Business Overview
11.4.3 DiaSorin Prostate Cancer Testing Introduction
11.4.4 DiaSorin Revenue in Prostate Cancer Testing Business (2018-2023)
11.4.5 DiaSorin Recent Development
11.5 bioMeriux
11.5.1 bioMeriux Company Detail
11.5.2 bioMeriux Business Overview
11.5.3 bioMeriux Prostate Cancer Testing Introduction
11.5.4 bioMeriux Revenue in Prostate Cancer Testing Business (2018-2023)
11.5.5 bioMeriux Recent Development
11.6 Roche
11.6.1 Roche Company Detail
11.6.2 Roche Business Overview
11.6.3 Roche Prostate Cancer Testing Introduction
11.6.4 Roche Revenue in Prostate Cancer Testing Business (2018-2023)
11.6.5 Roche Recent Development
11.7 MDx Health
11.7.1 MDx Health Company Detail
11.7.2 MDx Health Business Overview
11.7.3 MDx Health Prostate Cancer Testing Introduction
11.7.4 MDx Health Revenue in Prostate Cancer Testing Business (2018-2023)
11.7.5 MDx Health Recent Development
11.8 Beckman Coulter
11.8.1 Beckman Coulter Company Detail
11.8.2 Beckman Coulter Business Overview
11.8.3 Beckman Coulter Prostate Cancer Testing Introduction
11.8.4 Beckman Coulter Revenue in Prostate Cancer Testing Business (2018-2023)
11.8.5 Beckman Coulter Recent Development
11.9 Myriad Genetics
11.9.1 Myriad Genetics Company Detail
11.9.2 Myriad Genetics Business Overview
11.9.3 Myriad Genetics Prostate Cancer Testing Introduction
11.9.4 Myriad Genetics Revenue in Prostate Cancer Testing Business (2018-2023)
11.9.5 Myriad Genetics Recent Development
11.10 Ambry Genetics
11.10.1 Ambry Genetics Company Detail
11.10.2 Ambry Genetics Business Overview
11.10.3 Ambry Genetics Prostate Cancer Testing Introduction
11.10.4 Ambry Genetics Revenue in Prostate Cancer Testing Business (2018-2023)
11.10.5 Ambry Genetics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Genomic Health
OPKO
Siemens Healthcare
DiaSorin
bioMeriux
Roche
MDx Health
Beckman Coulter
Myriad Genetics
Ambry Genetics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.